Get the Stockscreener App
3.46
1.14%
-0.04
After Hours:
3.55
0.09
+2.60%
Sutro Biopharma Inc stock is traded at $3.46, with a volume of 519.26K.
It is down -1.14% in the last 24 hours and down -24.29% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
See More
Previous Close:
$3.50
Open:
$3.51
24h Volume:
519.26K
Relative Volume:
0.72
Market Cap:
$276.63M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-1.4008
EPS:
-2.47
Net Cash Flow:
$-115.93M
1W Performance:
-3.62%
1M Performance:
-24.29%
6M Performance:
-38.76%
1Y Performance:
-0.29%
1-Day Range:
$3.335
$3.61
1-Week Range:
$3.2215
$3.6424
52-Week Range:
$2.005
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
STRO (Sutro Biopharma) Enterprise Value : $-114.2 Mil (As of Sep. 28, 2024) - GuruFocus.com
Check out these key findings about Sutro Biopharma Inc (STRO) - SETE News
STRO’s 2023 Market Dance: Down -20.75% – Time to Invest? - The InvestChronicle
Sutro Biopharma Inc (STRO) presents a great opportunity, but the stock is slightly undervalued - US Post News
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology - Seeking Alpha
Sutro Biopharma Inc’s Market Journey: Closing Weak at 3.77, Down -3.83 - The Dwinnex
Bank of New York Mellon Corp Increases Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Institutional investors may overlook Sutro Biopharma, Inc.'s (NASDAQ:STRO) recent US$43m market cap drop as long-term gains remain positive - Simply Wall St
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players - Benzinga
Ready to Jump After Recent Trade: Sutro Biopharma Inc (STRO) - SETE News
UBS Group AG Adjusts Stake in Spirent Communications - TipRanks
Sonoma stock soars after expanded indications for its flagship drug announced - Kursiv Media
UBS Group AG Ups Stake in Spirent Communications - TipRanks
Serpin Pharma and Uniklinikum Erlangen Team Up for a Clinical Trial to Prevent Acute Kidney Injury - EIN News
Can you now get a good deal on Sutro Biopharma Inc’s shares? - US Post News
Sutro Biopharma (NASDAQ:STRO) Given “Buy” Rating at HC Wainwright - Defense World
Sutro Biopharma (NASDAQ:STRO) Receives “Market Outperform” Rating from JMP Securities - Defense World
Sutro Biopharma Inc (STRO Stock: A Sea of Opportunity - The InvestChronicle
Analyst upbeat on Sutro Biopharma shares, cites competitive ORR for Luvelta+bev - Investing.com Canada
Principal Financial Group Inc. Cuts Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Analyst Expectations For Sutro Biopharma's Future - Benzinga
Sutro Biopharma's (STRO) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
STROSutro Biopharma, Inc. Latest Stock News & Market Updates - StockTitan
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - ForexTV.com
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO - EIN News
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average PT from Analysts - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Acadian Asset Management LLC Grows Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Purchased by Acadian Asset Management LLC - Defense World
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 - StockTitan
A stock that deserves closer examination: Sutro Biopharma Inc (STRO) - US Post News
An analyst sees good growth prospects for Sutro Biopharma Inc (STRO) - SETE News
Panagora Asset Management Inc. Increases Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Panagora Asset Management Inc. Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
SG Americas Securities LLC Sells 6,421 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Examining Sutro Biopharma Inc (STRO) more closely is necessary - US Post News
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why - MSN
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why - Zacks Investment Research
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why - Yahoo Finance
STRO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise - Simply Wall St
Sutro Biopharma commences Phase II trial of luvelta for lung cancer - Yahoo Finance
Sutro Biopharma commences Phase II trial of luvelta for lung cancer - Clinical Trials Arena
Sutro Biopharma initiates phase 2 lung cancer study - Investing.com India
Sutro Biopharma initiates phase 2 lung cancer study - Investing.com
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts - Simply Wall St
Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer - Marketscreener.com
Market Highlights: Sutro Biopharma Inc (STRO) Ends on a High Note at 4.77 - The Dwinnex
Sutro Biopharma Inc (STRO) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):